Stanhope sets up White City covid mutant monitoring lab

stanhope

West London site is growing hub for pharma and life sciences industries

A sequencing laboratory for covid mutant monitoring has been temporarily installed at Stanhope’s Gateway East site in White City, west London, to help in the fight against the pandemic.

Stanhope along with Mitsui Fudosan and AIMCo, the Japanese developer and Canadian pension fund which between them own a majority stake in the firm, said the new monitoring facility has been set up alongside a larger installation of rapid response shipping-container laboratories for covid-19 PCR testing.

Already registered? Login here

To continue enjoying Building.co.uk, sign up for free guest access

Existing subscriber? LOGIN

 

Stay at the forefront of thought leadership with news and analysis from award-winning journalists. Enjoy company features, CEO interviews, architectural reviews, technical project know-how and the latest innovations.

  • Limited access to building.co.uk
  • Breaking industry news as it happens
  • Breaking, daily and weekly e-newsletters

Get your free guest access  SIGN UP TODAY

Gated access promo

Subscribe now for unlimited access

 

Subscribe to Building today and you will benefit from:

  • Unlimited access to all stories including expert analysis and comment from industry leaders
  • Our league tables, cost models and economics data
  • Our online archive of over 10,000 articles
  • Building magazine digital editions
  • Building magazine print editions
  • Printed/digital supplements

Subscribe now for unlimited access.

View our subscription options and join our community